Appearing as a promising development in the struggle against obesity, the drug is capturing considerable interest . It combines properties of two established GLP-1 receptor agonists, dulaglutide , with an unique glucose-dependent peptide component. Early study findings have indicated substantial body decrease in people with excessive weight, poten